Drug intelligence / Profile preview

Myo-006

Development stage: Preclinical
Lead developer: MitoRx
Modality: Small Molecules
Administration: Injectable

Overview

Myo-006 is a mitochondrial-targeted small molecule being developed by MitoRx Therapeutics for the treatment of obesity and cardiometabolic diseases. Administered as an intermittent injection, Myo-006 functions as a mitochondrial metabolism modulator designed to restore or enhance mitochondrial function. This approach aims to address the underlying mitochondrial dysfunction associated with metabolic disorders, potentially offering a differentiated therapeutic profile compared to existing appetite-suppressing or GLP-1 receptor agonist therapies. As of early 2024, the program is in the preclinical stages of development and represents one of MitoRx's two core obesity programs, alongside the oral candidate Myo-404.

Beyond the preview

Go deeper on Myo-006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Myo-006.

Explore the full profile